HeartFlow, Inc. (HTFL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Robert Marcus
JPMorgan Chase & Co, Research Division

Hello, everyone. We’re going to get started here. I hope you had a good lunch. I’m Robbie Marcus, the med tech analyst at JPMorgan. Very happy to introduce CEO of HeartFlow, John Farquhar. John will give a presentation followed by some Q&A. John?

John Farquhar
President, CEO & Director

Great. Thank you, Robbie. I appreciate the time today. Great to be here. Good to see everybody. So I’ll jump into this. I’ll give everybody an overview of HeartFlow, and then I think we’ve got some time at the end for Q&A.

So just to set the stage here, and these are all themes that you’ll hear as I go through the presentation, but we are a software company. We use AI in everything we do. We deploy that software and that AI to the treatment diagnosis and management of coronary artery disease.

The company was founded in 2010, just down the road here from Stanford University. We had our first FDA clearance in 2014. And I’ve been the CEO for about 4.5 years now. So great to be here.

We currently target the symptomatic market. So these are patients that have some form of symptom for coronary artery disease, we calculate that at a $5 billion TAM.

Very pleased to announce we had tremendous progress in 2025. In the U.S., we now have an installed base of 1,465 accounts. We define an account as any hospital or clinic that has a coronary CCTA image or coronary CCTA piece of capital in it. And